Genmab — Maj 2021
-
May 6th. Jefferies Financial Group analyst P. Welford now anticipates that the company will earn $0.07 per share for the quarter, up from their previous estimate of $0.06. also Q3 2021 earnings at $0.09 EPS, Q4 2021 earnings at $0.18 EPS, FY2022 earnings at $0.61 EPS, FY2023 earnings at $1.06 EPS, FY2024 earnings at $1.42 EPS and FY2025 earnings at $1.96 EPS.
-
Det ligner en overskudsgrad på 25 % og en omsætning omkring 30 mia
-
i 2025
-
Is it fair to assume the marginal profit in 2025 is closer to 40 % than 20 % due to the high income from Dara which contribute with maybe 90 % profit?
-
I guess a fair benchmark is 20-25 % for revenue related to own products
-
-
EPS 1.96 2025 is to low. And more likely to be around 2.5-3.0... or I hope
-
If the margin is around 40 % it will reflect running cost of 18 bDKK - think about that number versus 2021
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind